WUXI BIO (02269.HK)  -0.600 (-4.000%)    Short selling $187.51M; Ratio 20.311%   announced that it will enhance its drug product (DP) capabilities at the company’s facility in Leverkusen, Germany, with a new sterile filling line for prefilled syringes (PFS) using isolator technology.

The company said that construction of the new line will optimize the design of the Leverkusen facility’s manufacturing layout to be more efficient for multi-product CRDMO use. The new line, with its capability to handle multiple syringe sizes (1 ml, 2.25 ml, and 3 ml) at a filling rate of up to 400 syringes per minute, enables flexible GMP production of at least 17 million syringes every year. This will be in addition to the existing sterile filling and freeze-drying line that has an annual capacity of approximately 10 million doses.

Construction is scheduled to commence recently, with the goal of achieving GMP compliance by 2026.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-11-22 16:25.)